ROVI announces the agreement to market Hirobriz Breezhaler y Ulunar Breezhaler en España


No votes yet
 
Related
ROVI reports operating revenue growth of 12% and net profit growth of 53%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
5 min
24/11/2020